Indeed, recent small-scale studies have shown that inclusion of a Th2-inducing agent, such as G-CSF (58, 59), in even myeloablative preparation regimens appears promising for use to prevent GVHD in clinical practice. Here, CSF3 is linked to graft versus host disease.